MinorNon-selective beta blocker×Bile acid preparations
Updated · Methodology
Mechanism
Ursodeoxycholic acid is absorbed in the small intestine, conjugated with glycine or taurine in the liver and secreted into bile. Apart from this and minor conversion by gut bacteria, it is not metabolised (Adisocol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Propranolol is almost completely absorbed, but the liver breaks down most of the dose on first pass, with CYP2D6, CYP1A2 and CYP2C19 involved (Inderal LA label, US Food and Drug Administration, FDA). According to one Spanish ursodeoxycholic acid SmPC, the effect of ursodeoxycholic acid on bile acid secretion makes it theoretically possible that the absorption of other lipophilic substances changes (Adisocol SmPC, AEMPS). The US label describes propranolol as highly lipophilic. The documents, however, report no observations of such an effect, and no document names this pair (Inderal LA label, FDA).
Symptoms
The documents describe no symptoms linked to this combination. Ursodeoxycholic acid commonly causes pasty stools or diarrhoea. During treatment of advanced primary biliary cholangitis, decompensation of liver cirrhosis has been seen very rarely (Adisocol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Propranolol commonly causes fatigue, bradycardia, cold extremities, sleep disturbances and nightmares (Sumial SmPC, AEMPS). In portal hypertension, liver function may deteriorate and hepatic encephalopathy may develop, and some reports suggest that propranolol may increase this risk (Sumial SmPC, AEMPS).
Management
No document names this pair, and the documents give no reason to change the doses of ursodeoxycholic acid or propranolol (ursodeoxycholic acid and propranolol labels, Spanish Agency of Medicines and Medical Devices, AEMPS, and US Food and Drug Administration, FDA). One Spanish ursodeoxycholic acid SmPC mentions the theoretical possibility that the absorption of lipophilic substances changes, without any instruction for action (Adisocol SmPC, AEMPS). Another Spanish SmPC advises against combining ursodeoxycholic acid with potentially hepatotoxic drugs, but the propranolol documents do not class propranolol as one of them (Ursobilane and Sumial SmPCs, AEMPS). During the first 3 months of ursodeoxycholic acid treatment, AST, ALT and gamma-GT are measured every 4 weeks, then every 3 months (Adisocol SmPC, AEMPS). Propranolol is used with caution in decompensated cirrhosis and in impaired liver or kidney function, usually starting at the lowest dose of the range (Sumial SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Inderal LA (propranolol hydrochloride) prescribing information (ANI Pharmaceuticals) (2026)– FDA label, DailyMed setid 35d28979-36b1-4630-b85e-a44e0a443734, revised 08/2026, Precautions, Drug Interactions (Calcium Channel Blockers)
- AEMPS: Ficha técnica: Propranolol (Sumial 40 mg) (nº registro 42506), sección 4.5 (2021)– AEMPS, CIMA, nº registro 42506, revisión 09/2021, sección 4.5
- AEMPS: Ficha técnica: Ácido ursodesoxicólico, Ursobilane 150, 300 y 500 mg cápsulas (nº registro 65732), sección 4.5 (2026)– AEMPS, CIMA, nº registro 65732 (Ursobilane 300 mg cápsulas, Laboratorio Estedi), ficha técnica de 03/2026, secciones 4.1, 4.3, 4.4, 4.5 y 5.2
- AEMPS: Ficha técnica: Ácido ursodesoxicólico, Adisocol 500 mg cápsulas duras (nº registro 89784), sección 4.5 (2025)– AEMPS, CIMA, nº registro 89784 (Adisocol 500 mg cápsulas duras EFG, Glenmark), revisión 10/2025, secciones 4.4, 4.5, 4.8 y 5.2
- FDA: URSO 250 and URSO Forte (ursodiol) prescribing information (2023)– FDA, DailyMed setid e8fc4fc2-fe5c-4cba-b6e0-5ceaf2157a61 (Allergan), versión 19, 01/2023, sections 4, 5, 6 and 7